Giorgia Moranzoni

Giorgia Moranzoni

Auto-generated profile, based on publicly available information

Giorgia Moranzoni

LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2025 in Nature
Verified
Journal Article
Open access
PDF file
DBDavid A. Braun
David A. Braun
GMGiorgia Moranzoni
Giorgia Moranzoni
VCVipheaviny Chea
Vipheaviny Chea
BMBradley A McGregor
Bradley A McGregor
EBEryn Blass
Eryn Blass
TCToni K. Choueiri
Toni K. Choueiri
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens1,2,3,4,5,6. However, whether such responses can target cancer driver mutations, lead to immune recognition of a patient’s tumour and result in clinical activity are largely unknown. These questions are of particular interest for patients who have tumours with a low mutational burden. Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine. At a median follow-up of 40.2 months after surgery, none of the 9 participants enrolled in the study had a recurrence of RCC. No dose-limiting toxicities were observed. All patients generated T cell immune responses against the PCV antigens, including to RCC driver mutations in VHL, PBRM1, BAP1, KDM5C and PIK3CA. Following vaccination, there was a durable expansion of peripheral T cell clones. Moreover, T cell reactivity against autologous tumours was detected in seven out of nine patients. Our results demonstrate that neoantigen-targeting PCVs in high-risk RCC are highly immunogenic, capable of targeting key driver mutations and can induce antitumour immunity. These observations, in conjunction with the absence of recurrence in all nine vaccinated patients, highlights the promise of PCVs as effective adjuvant therapy in RCC.

22 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
GMGiorgia Moranzoni
Giorgia Moranzoni
LJLasse Vedel Jørgensen
Lasse Vedel Jørgensen
JCJavier Herranz del Cerro
Javier Herranz del Cerro
AAAntoine Andreoletti
Antoine Andreoletti
MHMagnus Haraldson Høie
Magnus Haraldson Høie
LOLars Rønn Olsen
Lars Rønn Olsen
Chimeric antigen receptor (CAR) cell therapy has achieved transformative clinical success through targeting of CD19 in refractory B cell malignancies, but extension of this strategy to solid tumors, other hematological malignancies, and autoimmune disease has exposed the complexity of target selection. Antigen abundance alone is not sufficient to define a suitable CAR target. Instead, therapeutic efficacy and safety are shaped by a broader set of molecular features, including isoform usage, subcellular localization, secretion, epitope stability, and the structural context in which antibody-derived binding domains engage their target. At the same time, advances in transcriptomics, structural biology, and artificial intelligence (AI)-enabled prediction now make it possible to assess many of these properties systematically. Here, we outline the principal molecular features that characterize effective and safe CAR targets and present a practical framework that integrates public datasets with computational and AI-based tools for their evaluation. Using HER2 as an illustrative case, we show how isoform-resolved expression, single-cell analyses, topology prediction, structure modelling, epitope mapping, and in silico binding analyses can reveal liabilities that are not captured by conventional target-expression screens alone. This framework provides a systematic strategy to prioritize targets and epitopes, guide preclinical investigation, and de-risk clinical translation. We anticipate that such integrative workflows will become increasingly important for moving CAR target discovery from descriptive expression analysis towards informed therapeutic design.